The Hair Loss Encyclopedia

Search

for
Search:

GlossaryBelimumab

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 36 results

research Low Disease Activity—Irrespective of Serologic Status at Baseline—Associated with Reduction of Corticosteroid Dose and Number of Flares in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Real-Life Observational Study

70 citations, February 2018 in “Seminars in Arthritis and Rheumatism”

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Real-Life Experience with Belimumab in Systemic Lupus Erythematosus: Control of Disease Activity and Flares in a Multicenter Cohort

research Real-Life Experience with Belimumab in Systemic Lupus Erythematosus: Control of Disease Activity and Flares in a Multicenter Cohort

2 citations, June 2017

Belimumab effectively controls SLE disease activity and reduces steroid use.

Acute And Subacute Skin Manifestations Of Systemic Lupus Erythematosus Are Associated With An Earlier Response To Belimumab Than The Chronic Phenotype: Preliminary Data From The New Nation-Wide Cohort Of Belimumab In Real Life Setting Study—New Joint And Skin (BERLISS-NEJS)

research Acute And Subacute Skin Manifestations Of Systemic Lupus Erythematosus Are Associated With An Earlier Response To Belimumab Than The Chronic Phenotype: Preliminary Data From The New Nation-Wide Cohort Of Belimumab In Real Life Setting Study—New Joint And Skin (BERLISS-NEJS)

June 2024

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Achievement of Low Disease Activity in Lupus Patients Treated with Belimumab Is Independent of Serologic Status at Baseline: A Real-Life Observational Study

research Achievement of Low Disease Activity in Lupus Patients Treated with Belimumab Is Independent of Serologic Status at Baseline: A Real-Life Observational Study

June 2018

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

The Future of Systemic Lupus Erythematosus Treatment: The Promise of Selective Immunotherapies, Anifrolumab and Belimumab, Compared to Blanket Immunosuppressives

research The Future of Systemic Lupus Erythematosus Treatment: The Promise of Selective Immunotherapies, Anifrolumab and Belimumab, Compared to Blanket Immunosuppressives

August 2024

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

View more "belimumab" in research →

Community Join

0 / 0 results

— no results